Sydney Lupkin
Sydney Lupkin is the pharmaceuticals correspondent for NPR.
She was most recently a correspondent at Kaiser Health News, where she covered drug prices and specialized in data reporting for its enterprise team. She's reported on how tainted drugs can reach consumers, how companies take advantage of rare disease drug rules and how FDA-approved generics often don't make it to market. She's also tracked pharmaceutical dollars to patient advocacy groups and members of Congress. Her work has won the National Press Club's Joan M. Friedenberg Online Journalism Award, the National Institute for Health Care Management's Digital Media Award and a health reporting award from the Society for Advancing Business Editing and Writing.
Lupkin graduated from Boston University. She's also worked for ABC News, VICE News, MedPage Today and The Bay Citizen. Her internship and part-time work includes stints at ProPublica, The Boston Globe, The Boston Herald, The New England Center for Investigative Reporting and WCVB.
-
After Hurricane Helene flooded an IV fluid factory in North Carolina, the government and industry are trying to mitigate shortages. -
Remnants of Hurricane Helene shut down a North Carolina factory that supplies critical IV fluids to hospitals across the country. There's no timeline for when production will resume at the facility. -
A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to schizophrenia treatment. The Food and Drug Administration approved it Thursday. -
The Food and Drug Administration, as expected, approved KarXT, the first new type of drug for schizophrenia in decades. It appears to be effective, but its main advantage is milder side effects.
-
The Federal Trade Commission said pharmacy benefit managers created a "perverse drug rebate system" that artificially inflated the cost of insulin. -
The drug companies behind blockbuster weight loss and diabetes treatments have signaled that supply problems could soon be over, but many patients still have trouble getting the medicines. -
For six of the 10 drugs that Medicare negotiated to lower prices, the net prices aren't any better than the ones insurers already get. But there may be a change in patients' choices of medicines.
-
President Biden and Vice President Harris are using their first recent joint appearance to talk about prescription drug prices.
-
The White House announced new Medicare drug prices for 10 medicines popular with beneficiaries. It's the first time the federal program has negotiated lower prices with the pharmaceutical industry. -
Medicare's new authority to negotiate lower prescription drug prices represents a signature accomplishment of the Biden-Harris administration. Here's what to know as the first set of talks wraps up.
